|Day Low/High||46.40 / 50.35|
|52 Wk Low/High||41.67 / 91.34|
The most recent short interest data has been released for the 01/31/2018 settlement date, which shows a 919,934 share decrease in total short interest for Ultragenyx Pharmaceutical Inc , to 4,819,058, a decrease of 16.03% since 01/12/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Ultragenyx Pharmaceutical Inc.
Early Evidence of Normalization of Ureagenesis in One Patient in Lowest-Dose Cohort and Acceptable Initial Safety Profile
Ultragenyx to Provide Additional Information to FDA for Consideration of Possible Early Filing on Current Phase 2 Data
If approved, Burosumab would be the first targeted disease-modifying treatment for XLH
The Cambridge, Mass.-based Ironwood unveiled top-line data from a pair of Phase 2a studies evaluating IW-1973 in patients that have type 2 diabetes and hypertension.
Further improvement in disease symptoms and fracture healing observed through 48 weeks of treatment with burosumab
The hotly debated tax reform championed by the Trump White House needs to be paid for by spending cuts. One proposed change could eliminate the tax credit for companies developing treatments through the Orphan Drug Act.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AINV, AMOT, ANIP, EXFO, EXPR, INBK, LIND, LNN, LTM, MJCO, MYRG, SGEN, WEYS Downgrades: BAM, ESRT, IAG, PGRE, RRTS, SSRM Initiations: RARE Read on to get TheStreet Quant Ratings' detailed report:
First Cohort Data Expected in Early 2018
Ultragenyx to Host Conference Call Today at 5:00pm ET
Regulatory Review Process Proceeding as Expected; PDUFA date of April 17, 2018
Dimension Therapeutics said Oct. 3 it has agreed to sell to Ultragenyx Pharmaceutical for $6 a share in cash or about $151M.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.